fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Merck Beats Q2 Estimates – Keytruda Growth Remains Strong

By John F. Heerdink, Jr.

Merck & Co., Inc. (MRK) reported quarterly revenue beating Wall Street’s estimates, as sales for its blockbuster cancer drug Keytruda remained strong and demand for its Gardasil vaccine also rebounded. The company’s second-quarter sales increased 22% to $11.40 billion, beating estimates of $11.10 billion. Merck reported adjusted earnings of $1.31 per share for the quarter, in line with analyst estimates.

Merck expects to have late-stage data for its COVID-19 antiviral, molnupiravir, in October, informed Chief Financial Officer Caroline Litchfield. Sales of cancer immunotherapy Keytruda increased 23% to $4.18 billion in the quarter, meeting estimates.

Demand for Gardasil, its vaccine to prevent cancers linked to the human papillomavirus, also recovered in the second quarter as patients got back to routine medical visits that were amiss during the pandemic. Gardasil sales increased 88% to $1.23 billion, ahead of analysts’ estimates of $991.38 million.

Recent improvements in the supply chain for the vaccine will drive “very strong sequential and year-over-year growth for Gardasil in the back half of the year, especially in ex-U.S. markets,” stated Franklin Clyburn, president of Merck’s human health business.


Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.


If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 
 
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

(Read Original Story: Merck sees recovery in non-COVID vaccine demand as quarterly sales beat estimates in Reuters)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us